Jul 31, 2026 04:30AM
May 22, 2026 09:30AM
May 22, 2026 08:00AM
May 22, 2026 08:00AM
May 15, 2026 06:31PM
Apr 13, 2026 07:00AM
Apr 1, 2026 08:01AM Nuvation Bio acquires Japan rights to safusidenib from Daiichi Sankyo
Apr 1, 2026 08:00AM
Mar 9, 2026 02:30AM
Feb 19, 2026 02:30AM
Feb 3, 2026 02:30AM
Jan 19, 2026 02:30AM
Jan 13, 2026 07:00AM
Jan 13, 2026 07:00AM TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Dec 22, 2025 02:30AM
Dec 22, 2025 02:30AM
Dec 22, 2025 02:30AM
Dec 15, 2025 02:30PM
Dec 15, 2025 02:30PM
Dec 15, 2025 09:00AM
Dec 9, 2025 07:01AM Daiichi Sankyo begins phase 3 ovarian cancer trial for ENHERTU
Dec 9, 2025 07:00AM
Oct 30, 2025 09:00PM
Oct 30, 2025 09:00PM
Oct 19, 2025 08:45AM
Oct 19, 2025 08:45AM
Oct 19, 2025 02:30AM
Oct 18, 2025 10:30AM ENHERTU shows 67% response rate in breast cancer trial
Oct 18, 2025 10:30AM
Oct 18, 2025 10:30AM
Oct 18, 2025 10:30AM
Oct 17, 2025 10:00AM
Oct 17, 2025 10:00AM
Oct 6, 2025 02:30AM
Oct 1, 2025 07:00AM FDA accepts ENHERTU application for early-stage breast cancer treatment
Oct 1, 2025 07:00AM
Sep 29, 2025 02:30AM
Sep 29, 2025 02:30AM
Sep 24, 2025 02:30AM
Sep 15, 2025 07:00AM
Sep 7, 2025 10:45AM
Sep 7, 2025 10:45AM Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Aug 18, 2025 07:00AM
Jul 17, 2025 08:00AM
Jul 9, 2025 08:00AM
Jun 23, 2025 05:05PM
Jun 18, 2025 07:00AM
Jun 9, 2025 08:00AM
Jun 2, 2025 08:06AM Daiichi Sankyo, AstraZeneca (AZN): ENHERTU Plus Pertuzumab Reduced the Risk of Disease Progression or Death
Jun 2, 2025 08:00AM

327,799 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All